Chikungunya Vaccines 2022
Chikungunya Vaccines For 2022
Like all vaccines under development, Chikungunya vaccine candidates investigate various technologies, such as live-attenuated virus vaccines, inactivated viral vaccines, recombinant viral vaccines, chimeric-alphavirus candidates, DNA vaccines, and virus-like particles, which focus on optimizing the balance between immunogenicity and safety.
As of April 27, 2022, the U.S. FDA has not approved a Chikungunya vaccine.
Chikungunya Vaccine Candidates
VLA1553 is a monovalent, single dose, live-attenuated vaccine candidate. VLA1553 is based on an infectious clone (CHIKV LR2006-OPY1) attenuated by deleting a significant part of the gene encoding the non-structural replicase complex protein nsP3 for protection against various Chikungunya virus outbreak phylogroups and strains. VLA1553 shows fully sustained titers one year after a single vaccination, says Valneva SE.
CHIKV-VLP vaccine candidate is a multi-protein structure that mimics the organization and conformation of naturally occurring viruses without the viral genome, promoting a more robust immune response and increased antibody production. The CHIKV VLP vaccine candidate is licensed by the National Institute of Allergy and Infectious Diseases. In addition, it received Fast Track designation from the U.S. FDA in May 2018.
MV-CHIK is a Chikungunya vaccine candidate utilizing Themis' measles vector platform. MV-CHIK consists of a recombinant live Schwarz-strain measles-vectored vaccine expressing chikungunya virus structural proteins. In addition, Themis' vaccination vector can incorporate large recombinant genes coding for selected antigens into its genome.
mRNA-1944 encodes a fully human IgG antibody isolated initially from B cells of a patient with a prior history of potent immunity against Chikungunya infection. It comprises two mRNAs encode this anti-Chikungunya antibody's heavy and light chains within lipid nanoparticle technology.
Chikungunya Vaccine News For 2019 - 2022
March 31, 2022 - Dr. Mike Ryan, head of the WHO’s Emergency Programme, explained the “broad but related threats” posed by Dengue, Yellow fever, Chikungunya, and Zika in different parts of the world.
March 17, 2022 - The South Delhi Municipal Corporation, located in New Delphi, India, reported several chikungunya cases that were not recorded correctly during 2022. Previously, chikungunya was declared a “notifiable disease” under the Epidemic Diseases Act as per orders issued by the Delhi government on October 14, 2021.
March 8, 2022 - Valneva SE announced the successful completion of the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553. The positive final analysis included six-month follow-up data and confirmed the topline results reported in August 2021. Under the accelerated approval pathway, the company expects to commence the pre-submission process with the U.S. FDA in the second quarter of 202y.
February 22, 2022 - U.K.-based Emergex Vaccines Holding Limited announced it was awarded a £490,525 grant by the UK government's Department of Health and Social Care to advance a synthetic T cell vaccine candidate for the Chikungunya virus.
January 31, 2022 - Prof. Dimas Tadeu Covas, President of Instituto Butantan, which sponsors the Valneva phase 3 trial in Brazil, commented in a press release, "VLA1553 is currently the most clinically advanced chikungunya vaccine candidate worldwide, having successfully completed Phase 3 in adults."
December 21, 2021 - Valneva SE reported the VLA1553-302 clinical trial met its primary endpoint, demonstrating that three consecutively manufactured vaccine lots elicited equivalent immune responses measured by neutralizing antibody titer GMT ratios on Day 29 after vaccination with VLA-1553. Lot-to-lot trials show manufacturing consistency, one of the standard requirements for vaccine licensure.
November 2, 2021 - Local media in Mumbi, India, confirmed about 48 Chikungunya cases during 2021.
October 19, 2021 - The U.S. CDC reported 16 chikungunya virus disease cases in travelers returning from affected areas.
October. 15, 2021 - Emergent BioSolutions Inc. announced the first participant dosed in its pivotal phase 3 study evaluating the safety and immunogenicity of its investigational chikungunya virus virus-like particle vaccine candidate, CHIKV VLP, in a single dose.
August 5, 2021 - Valneva SE announced positive topline results from the Phase 3 pivotal trial of its chikungunya vaccine candidate, VLA1553. The trial, involving 4,115 adults aged 18 years and above, across 44 sites in the U.S., met its primary endpoint inducing protective CHIKV neutralizing antibody titers in 98.5% of participants 28 days after receiving a single shot (264 of 268 subjects from the per-protocol subgroup tested for immunogenicity, 95%CI: 96.2-99.6). In addition, the seroprotection rate result of 98.5% exceeded the 70% threshold (for non-acceptance) agreed with the U.S. FDA.
September 12, 2019 - Moderna, Inc. announced positive data in the first analysis of safety and activity in its Phase 1 study evaluating escalating doses of mRNA-1944 administered via intravenous infusion in healthy adults. mRNA-1944 encodes for an antibody (CHKV-24) with activity against the chikungunya virus.
Note: This information has been fact-checked by healthcare providers.